{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:50:12Z","timestamp":1786463412259,"version":"build-2736575974"},"reference-count":170,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The advent of therapeutic antibodies has revolutionized the treatment landscape for various diseases, particularly in oncology and immunology. These highly specific biologic agents bind cell surface proteins, offering targeted therapeutic strategies with potentially fewer side effects compared to traditional treatments. However, the increasing use of these antibodies has introduced new challenges in transfusion and transplantation diagnostics. This review article explores how therapeutic biologics interfere with serological and pre-transfusion testing, focusing on biologics that target CD20, CD38, and CD47, discusses current remedies and solutions to mitigate these interferences, and considers possible interferences from new drugs and drug targets.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1888597","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T13:41:35Z","timestamp":1786455695000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic biologics interference in serological and pre-transfusion testing"],"prefix":"10.3389","volume":"17","author":[{"given":"Philipp","family":"Trummer","sequence":"first","affiliation":[{"name":"imusyn GmbH & Co. KG","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora P.","family":"Habicht","sequence":"additional","affiliation":[{"name":"imusyn GmbH & Co. KG","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin A.","family":"Scharberg","sequence":"additional","affiliation":[{"name":"SYNLAB MVZ Leinfelden GmbH","place":["Leinfelden-Echterdingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Schneewei\u00df","sequence":"additional","affiliation":[{"name":"imusyn GmbH & Co. KG","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti\u2013tumor necrosis factor therapy: Results of a multicenter, randomized, double\u2010blind, placebo\u2010controlled, phase III trial evaluating primary efficacy and safety at twenty\u2010four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000296031.41424.f8","article-title":"Long-term results of ABO-incompatible kidney transplantation with antigen-specific immunoadsorption and rituximab","volume":"84","author":"Genberg","year":"2007","journal-title":"Transplantation"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41598-021-82841-w","article-title":"Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis","volume":"11","author":"Luo","year":"2021","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S315174","article-title":"Profile of ofatumumab in the treatment of multiple sclerosis: Design, development and place in therapy","volume":"18","author":"Awada","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb8008","article-title":"Binding mechanisms of therapeutic antibodies to human CD20","volume":"369","author":"Kumar","year":"2020","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: Mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin Oncol"},{"key":"B12","article-title":"Mechanisms of action of CD20 antibodies","volume":"2","author":"Boross","year":"2012","journal-title":"Am J Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1761","article-title":"Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts","volume":"101","author":"Cragg","year":"2003","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell\u2013mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/TP.0000000000003686","article-title":"Obinutuzumab in kidney transplantation: effect on B-cell counts and crossmatch tests","volume":"106","author":"NasrAllah","year":"2022","journal-title":"Transplantation"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M308802200","article-title":"Store-operated cation entry mediated by CD20 in membrane rafts","volume":"278","author":"Li","year":"2003","journal-title":"J Biol Chem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.51.5.364","article-title":"Levels of expression of CD19 and CD20 in chronic B cell leukaemias","volume":"51","author":"Ginaldi","year":"1998","journal-title":"J Clin Pathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol Baltim Md 1950"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic Malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1186\/s12967-024-05768-6","article-title":"CD38 as theranostic target in oncology","volume":"22","author":"Bocuzzi","year":"2024","journal-title":"J Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1055\/a-1521-8045","article-title":"Immunh\u00e4matologische daratumumab-interferenz im verlauf einer myelomtherapie","volume":"11","author":"Gr\u00fcger","year":"2021","journal-title":"Transfusionsmedizin"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2023.06.018","article-title":"Daratumumab for antibody-mediated rejection: Is it time to target the real culprit","volume":"23","author":"De Nattes","year":"2023","journal-title":"Am J Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.08.020","article-title":"Open-label phase 1\/2 study of daratumumab-based desensitization before kidney transplantation","volume":"9","author":"Pilon","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1087597","article-title":"Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodies","volume":"13","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000287","article-title":"Isatuximab monotherapy for desensitization in highly sensitized patients awaiting kidney transplant","volume":"35","author":"Vincenti","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4763\u2013","DOI":"10.1182\/blood-2021-150783","article-title":"A phase 1, open-label, dose-escalation study of the safety and efficacy of anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma","volume":"138","author":"Chakraborty","year":"2021","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13045-022-01395-0","article-title":"FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma","volume":"15","author":"Zhang","year":"2022","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00018","article-title":"Advances in anti-tumor treatments targeting the CD47\/SIRP\u03b1 axis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027222","article-title":"Targeting CD47: many misses; hopeful for a hit","volume":"145","author":"Wilde","year":"2025","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40364-023-00456-x","article-title":"The landscape overview of CD47-based immunotherapy for hematological Malignancies","volume":"11","author":"Yang","year":"2023","journal-title":"biomark Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.02.30","article-title":"Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy","volume":"9","author":"Huang","year":"2017","journal-title":"J Thorac Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2327\u2013","DOI":"10.1182\/blood-2018-99-115674","article-title":"RBC-specific CD47 pruning confers protection and underlies the transient anemia in patients treated with anti-CD47 antibody 5F9","volume":"132","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-020-00930-1","article-title":"Role of CD47 in hematological Malignancies","volume":"13","author":"Eladl","year":"2020","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005517","article-title":"Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity","volume":"10","author":"Qu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4063\u2013","DOI":"10.1182\/blood-2019-122793","article-title":"TJC4, a differentiated anti-CD47 antibody with novel epitope and RBC sparing properties","volume":"134","author":"Meng","year":"2019","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15033","article-title":"Monoclonal anti-CD47 interference in red cell and platelet testing","volume":"59","author":"Velliquette","year":"2019","journal-title":"Transfusion (Paris)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-493-7_13","article-title":"Complement-dependent cytotoxicity crossmatch","volume":"1034","author":"Pe\u00f1a","year":"2013","journal-title":"Transplant Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036527","article-title":"Crossmatch assays in transplantation: Physical or virtual?: A review","volume":"102","author":"Rocha","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198207000-00005","article-title":"Antigenic specificity of antibody reactive in the antiglobulin-augmented lymphocytotoxicity test","volume":"34","author":"Fuller","year":"1982","journal-title":"Transplantation"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/trf.18367","article-title":"Anti-CD47 drug interference in pre-transfusion testing can be overcome by antigen masking","volume":"63","author":"Habicht","year":"2025","journal-title":"Transfusion (Paris)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4103\/0973-6247.214358","article-title":"Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody","volume":"11","author":"Lin","year":"2017","journal-title":"Asian J Transfus Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.humimm.2015.07.177","article-title":"Residual serum rituximab induces false positive flow cytometric B cell crossmatch more than 6 months post-infusion","volume":"76","author":"Lazar-Molnar","year":"2015","journal-title":"Hum Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13150","article-title":"When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy","volume":"55","author":"Oostendorp","year":"2015","journal-title":"Transfusion (Paris)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/vox.70251","article-title":"Effective resolution of daratumumab\u2010induced false\u2010positive antibody screening with commercial reagents","volume":"121","author":"Kim","year":"2026","journal-title":"Vox Sang"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12664","article-title":"Two case reports involving therapeutic monoclonal anti\u2010CD47 (Hu5F9\u2010G4), it\u2019s effect on compatibility testing and subsequent selection of components for transfusion","volume":"30","author":"Reyland","year":"2020","journal-title":"Transfus Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/cyto.990140212","article-title":"Cd20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes","volume":"14","author":"Hultin","year":"1993","journal-title":"Cytometry"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1159\/000495773","article-title":"Daratumumab interference in pretransfusion testing is overcome by addition of daratumumab Fab fragments to patients\u2019 plasma","volume":"46","author":"Werle","year":"2019","journal-title":"Transfus Med Hemotherapy"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12370","article-title":"CD 38 expression in early B \u2010cell precursors contributes to extracellular signal\u2010regulated kinase\u2010mediated apoptosis","volume":"144","author":"Romero\u2010Ram\u00edrez","year":"2015","journal-title":"Immunology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol Rev"},{"key":"B53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/mp.a002870.01","article-title":"CD47 (Cluster of differentiation 47)","volume":"25","author":"Kaur","year":"2021","journal-title":"Atlas Genet Cytogenet Oncol Haematol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001796","article-title":"CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLC\u03b31 activation: evidence from mice and humans","volume":"12","author":"Martinez-Torres","year":"2015","journal-title":"PloS Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005857","article-title":"CD47 expression is critical for CAR T-cell survival in vivo","volume":"11","author":"Beckett","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2015.04.004","article-title":"Interference of therapeutic antibodies used in desensitization protocols on lymphocytotoxicity crossmatch results","volume":"32","author":"Milongo","year":"2015","journal-title":"Transpl Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/4534898","article-title":"False positive B-cells crossmatch after prior rituximab exposure of the kidney donor","volume":"2016","author":"Desoutter","year":"2016","journal-title":"Case Rep Transplant"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2013.08.278","article-title":"Very low residual concentrations of rituximab long after infusion still induce positive B-cell complement-dependent cytotoxicity-crossmatch","volume":"74","author":"Philippe","year":"2013","journal-title":"Hum Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17137","article-title":"Anti\u2010CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping","volume":"62","author":"Chami","year":"2022","journal-title":"Transfusion (Paris)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/tme.13139","article-title":"Antigen masking indirect antiglobulin test can mitigate the interference of Mezagitamab, a novel anti\u2010 CD38 antibody, in serological pre\u2010transfusion testing","volume":"35","author":"Habicht","year":"2025","journal-title":"Transfus Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjhh.2017.09.003","article-title":"Transfusion management for patients taking an anti-CD38 monoclonal antibody","volume":"40","author":"Bub","year":"2018","journal-title":"Hematol Transfus Cell Ther"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion (Paris)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11206059","article-title":"Daratumumab interferes with allogeneic crossmatch impacting immunological assessment in solid organ transplantation","volume":"11","author":"Ho","year":"2022","journal-title":"J Clin Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13061005","article-title":"Antibody therapeutics as interfering agents in flow cytometry crossmatch for organ transplantation","volume":"13","author":"Kueht","year":"2023","journal-title":"J Pers Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100070","article-title":"CD47\u2013SIRP\u03b1-targeted therapeutics: status and prospects","volume":"13","author":"Maute","year":"2022","journal-title":"Immuno-Oncol Technol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1365-2249.2007.03545.x","article-title":"Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities","volume":"151","author":"Gonzalez-Quintela","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaf060","article-title":"Optimized strategy to mitigate daratumumab interference in blood bank testing: Reducing cost and time","volume":"164","author":"Yu","year":"2025","journal-title":"Am J Clin Pathol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2770\u2013","DOI":"10.1111\/trf.13267","article-title":"Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma","volume":"55","author":"Hannon","year":"2015","journal-title":"Transfusion (Paris)"},{"key":"B69","doi-asserted-by":"publisher","first-page":"20\u2013","DOI":"10.21037\/aob-25-37","article-title":"Transfusion with blood group genotype matching: advances, limitations, and challenges: a narrative review","volume":"10","author":"Castilho","year":"2025","journal-title":"Ann Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13174","article-title":"An alternative method to dithiothreitol treatment for antibody screening in patients receiving daratumumab","volume":"55","author":"Schmidt","year":"2015","journal-title":"Transfusion (Paris)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02616","article-title":"Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies","volume":"9","author":"Lancman","year":"2018","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-749432","article-title":"Daratumumab (anti-CD38) induces loss of CD38 on red blood cells","volume":"129","author":"Sullivan","year":"2017","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15142","article-title":"Immunotherapy: the good, the bad, the ugly, and the really ugly","volume":"59","author":"Branch","year":"2019","journal-title":"Transfusion (Paris)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2019.01.004","article-title":"Genetic variants within the erythroid transcription factor, KLF1, and reduction of the expression of Lutheran and other blood group antigens: Review of the In(Lu) phenotype","volume":"33","author":"Fraser","year":"2019","journal-title":"Transfus Med Rev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13476","article-title":"Compound heterozygosity of two novel RHAG alleles leads to a considerable disruption of the Rh complex","volume":"56","author":"Polin","year":"2016","journal-title":"Transfusion (Paris)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13789","article-title":"International validation of a dithiothreitol (DTT)\u2010based method to resolve the daratumumab interference with blood compatibility testing","volume":"56","author":"Chapuy","year":"2016","journal-title":"Transfusion (Paris)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17253","article-title":"Mitigation of therapeutic anti\u2010CD38 antibody interference with fab fragments: How well does it perform","volume":"63","author":"Habicht","year":"2023","journal-title":"Transfusion (Paris)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1983.00561.x-i1","article-title":"Disulfide bonds are a requirement for Kell and Cartwright (Yta) blood group antigen integrity","volume":"54","author":"Branch","year":"1983","journal-title":"Br J Haematol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.21307\/immunohematology-2019-162","article-title":"The production, serologic evaluation, and epitope mapping of ten murine monoclonal Dombrock antibodies","volume":"28","author":"Grodecka","year":"2012","journal-title":"Immunohematology"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.13726","article-title":"Dimerization of small integral membrane protein 1 promotes cell surface presentation of the Vel blood group epitope","volume":"594","author":"Kelley","year":"2020","journal-title":"FEBS Lett"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14900","article-title":"Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol\/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method)","volume":"58","author":"Hosokawa","year":"2018","journal-title":"Transfusion (Paris)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2450\/2020.0004-20","article-title":"New method for overcoming the interference produced by anti-CD38 monoclonal antibodies in compatibility testing","volume":"18","author":"Castro Izaguirre","year":"2020","journal-title":"Blood Transfus"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3692\u2013","DOI":"10.1182\/blood-2019-124289","article-title":"Optimum DTT concentration and treatment time for CD38 inactivation on RBCs analyzed by a newly-devised flow cytometric antibody binding assay","volume":"134","author":"Furumaki","year":"2019","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2021.1918916","article-title":"2-Mercaptoethanol (2-ME)-based IATs or Polybrene method mitigates the interference of daratumumab on blood compatibility tests","volume":"26","author":"Zhou","year":"2021","journal-title":"Hematology"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-5-21","article-title":"Characterization and phylogenetic epitope mapping of CD38 ADPR cyclase in the cynomolgus macaque","volume":"5","author":"Ferrero","year":"2004","journal-title":"BMC Immunol"},{"key":"B86","article-title":"Not all Anti-CD38 antibodies are created equal: The epitope of Felzartamab is partially DTT-resistant [Poster","volume-title":"Abstracts. MannheimTransfus Med Hemother","author":"Zeretzke","year":"2025"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.21307\/immunohematology-2020-029","article-title":"Use of trypsin in serologic investigation","volume":"35","author":"Novotny","year":"2019","journal-title":"Immunohematology"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16635","article-title":"Use of an in\u2010house trypsin\u2010based method to resolve the interference of daratumumab","volume":"61","author":"Ibeh","year":"2021","journal-title":"Transfusion (Paris)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12508","article-title":"Papain-treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti-CD38-based therapies","volume":"29","author":"Carre\u00f1o-Tarragona","year":"2019","journal-title":"Transfus Med Oxf Engl"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/tan.13073","article-title":"Pronase treatment improves flow cytometry crossmatching results","volume":"90","author":"Apithy","year":"2017","journal-title":"HLA"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/tan.13403","article-title":"Improved flow cytometry crossmatching in kidney transplantation","volume":"92","author":"Guillaume","year":"2018","journal-title":"HLA"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2024.0132","article-title":"Effects of various concentrations of pronase on flow cytometric crossmatching patients treated with rituximab and donor HLA-specific antibodies","volume":"44","author":"Kim","year":"2024","journal-title":"Ann Lab Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2011.01.005","article-title":"Impact of pronase on flow cytometric crossmatch outcome","volume":"72","author":"Hetrick","year":"2011","journal-title":"Hum Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2023.03.075","article-title":"Low expression loci and the use of pronase in flow cytometry crossmatch","volume":"55","author":"Silva","year":"2023","journal-title":"Transplant Proc"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2016.04.014","article-title":"Flow cytometry crossmatch reactivity with pronase-treated T cells induced by non-HLA autoantibodies in human immunodeficiency virus-infected patients","volume":"77","author":"Szewczyk","year":"2016","journal-title":"Hum Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15932","article-title":"Daudi cell stroma: An alternative to dithiothreitol to resolve daratumumab interference in pretransfusion testing","volume":"60","author":"Tremblay","year":"2020","journal-title":"Transfusion (Paris)"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.2450\/BloodTransfus.539","article-title":"Pretreatment with Daudi cells eliminates anti-CD47 monoclonal antibody interference in immunohematology testing","volume":"22","author":"Wei","year":"2024","journal-title":"Blood Transfus Trasfus Sangue"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011396","article-title":"Preanalytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing","volume":"138","author":"Ehrend","year":"2021","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16009","article-title":"Assessing and mitigating the interference of ALX148 , a novel CD47 blocking agent, in pretransfusion compatibility testing","volume":"60","author":"Kim","year":"2020","journal-title":"Transfusion (Paris)"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1155\/jimr\/7343647","article-title":"Resolving the interference of anti\u2010CD38 antibodies on blood compatibility assays using CD38 \u201cBaitbodies\u201d approach","volume":"2026","author":"Gnann","year":"2026","journal-title":"J Immunol Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2025.04.008","article-title":"Novel strategy for overcoming interference from anti-CD47 agents in pretransfusion testing","volume":"57","author":"Wei","year":"2025","journal-title":"Pathol (Phila)"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/vox.70269","article-title":"International multicentre evaluation of a new anti\u2010idiotypic anti\u2010daratumumab for resolving pre\u2010transfusion interferences","volume":"121","author":"Reggiani","year":"2026","journal-title":"Vox Sang"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17006","article-title":"Efficient neutralization of daratumumab in pretransfusion samples using a novel recombinant monoclonal anti\u2010idiotype antibody","volume":"62","author":"Aung","year":"2022","journal-title":"Transfusion (Paris)"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1159\/000534273","article-title":"Evorpacept-induced interference and application of a novel mitigation agent, Evo-NR, in pretransfusion testing","volume":"51","author":"Yoon","year":"2024","journal-title":"Transfus Med Hemotherapy"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3390\/antib9030041","article-title":"Solutions to avoid false positives for rituximab in pre-transplant crossmatches","volume":"9","author":"Colmenero Velazquez","year":"2020","journal-title":"Antibodies"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2017.11.006","article-title":"Pronase independent flow cytometry crossmatching of rituximab treated patients","volume":"79","author":"Alheim","year":"2018","journal-title":"Hum Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2021.01.016","article-title":"Abrogating biologics interference in flow cytometric crossmatching","volume":"82","author":"Franz","year":"2021","journal-title":"Hum Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/vox.70030","article-title":"Interferences caused by monoclonal antibody therapy: study of a new anti-daratumumab reagent","volume":"120","author":"Coluzzi","year":"2025","journal-title":"Vox Sang"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2406192121","article-title":"Complement activation by IgG subclasses is governed by their ability to oligomerize upon antigen binding","volume":"121","author":"Frischauf","year":"2024","journal-title":"Proc Natl Acad Sci"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1159\/000509028","article-title":"The manual polybrene method can be used for the pretransfusion test to mitigate daratumumab interference without a supplementary antiglobulin test","volume":"48","author":"Shao","year":"2021","journal-title":"Transfus Med Hemotherapy"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24891","article-title":"Better resolving of anti\u2010CD38 antibody interference with blood compatibility testing by using manual polybrene method compared with dithiothreitol\u2010pretreatment indirect antiglobulin test","volume":"37","author":"Feng","year":"2023","journal-title":"J Clin Lab Anal"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15202","article-title":"A blockage monoclonal antibody protocol as an alternative strategy to avoid anti\u2010CD38 interference in immunohematological testing","volume":"59","author":"Chinoca Ziza","year":"2019","journal-title":"Transfusion (Paris)"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S213510","article-title":"Overcoming drug interference in transfusion testing: a spotlight on daratumumab","volume":"12","author":"Nedumcheril","year":"2021","journal-title":"J Blood Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1804751","article-title":"F(ab\u2032)2 fragments to overcome daratumumab interference in transfusion tests","volume":"379","author":"Selleng","year":"2018","journal-title":"N Engl J Med"},{"key":"B115","first-page":"e70162","article-title":"Minimizing false-positive results from anti-CD20 antibody interference in crossmatch testing [Poster","volume-title":"HLA","author":"Trummer","year":"2025"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1726341","article-title":"A rabbit anti-human CD38 antibody for eliminating daratumumab and isatuximab interference in immunohematology testing","volume":"17","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1182\/blood-2019-131345","article-title":"Validation of daraex to resolve daratumumab-induced interferences in pre-transfusion screen tests","volume":"134","author":"Tenorio","year":"2019","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000564624.40514.b2","article-title":"PS1594 experience with the neutralizing agent DARAEX\u00ae in blood compatibility tests in patients treated with daratumumab","volume":"3","author":"Constantin","year":"2019","journal-title":"HemaSphere"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.17532\/jhs.2023.2612","article-title":"The importance of removing interference caused by Darzalex\u00ae(daratumumab) in pre-transfusion testing","volume":"13","author":"Dilberovi\u0107","year":"2023","journal-title":"J Health Sci"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12989","article-title":"Daratumumab interference in flow cytometric anti\u2010granulocyte antibody testing can be overcome using non\u2010human blocking antibodies","volume":"116","author":"Baig","year":"2021","journal-title":"Vox Sang"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1525892","article-title":"Case report: Single infusion of combined anti-CD20 and anti-CD38 monoclonal antibodies in pediatric refractory lupus nephritis","volume":"16","author":"Chiarenza","year":"2025","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164755","article-title":"Exploration of the therapeutic effects of CD47 and CD38 antibody combination in relapsed or refractory multiple myeloma (rrMM) and the correlation with CD47 and CD38 expression","volume":"140","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","first-page":"4089\u2013","DOI":"10.1182\/blood-2019-125310","article-title":"Anti-CD47 antibody, CC-90002, in combination with rituximab in subjects with relapsed and\/or refractory non-Hodgkin lymphoma (R\/R NHL)","volume":"134","author":"Abrisqueta","year":"2019","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1398508","article-title":"Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic Malignancies expressing CD38","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1038\/s41467-024-46310-y","article-title":"Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma","volume":"15","author":"Grandcl\u00e9ment","year":"2024","journal-title":"Nat Commun"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164746","article-title":"Trial in progress: First report of the phase 1\/2 study of the safety and efficacy of CPO107, a bispecific agent targeting CD20\/CD47 in CD20 expressing non-Hodgkin lymphoma (NHL)","volume":"140","author":"Skarbnik","year":"2022","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01805-9","article-title":"IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRP\u03b1, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRP\u03b1 interaction and Fc\u03b3R engagement by simultaneously binding to CD47 and CD20 of B cells","volume":"37","author":"Yu","year":"2023","journal-title":"Leukemia"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2310248","article-title":"CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin\u2019s lymphoma","volume":"16","author":"Zhu","year":"2024","journal-title":"mAbs"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1386361","article-title":"CD20-selective inhibition of CD47-SIRP\u03b1 \u201cdon\u2019t eat me\u201d signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab","volume":"7","author":"Van Bommel","year":"2018","journal-title":"OncoImmunology"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-020-0571-2","article-title":"Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential","volume":"18","author":"Ma","year":"2020","journal-title":"J Nanobiotechnology"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3390\/antib9040053","article-title":"Structure, function, and therapeutic use of IgM antibodies","volume":"9","author":"Keyt","year":"2020","journal-title":"Antibodies"},{"key":"B132","doi-asserted-by":"publisher","first-page":"3106\u2013","DOI":"10.1182\/blood-2019-125788","article-title":"Hexabody-CD38, a novel CD38 antibody with a hexamerization enhancing mutation, demonstrates enhanced complement-dependent cytotoxicity and shows potent anti-tumor activity in preclinical models of hematological Malignancies","volume":"134","author":"De Goeij","year":"2019","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13394","article-title":"Enhancing Fc\u2010mediated effector functions of monoclonal antibodies: the example of HexaBodies","volume":"328","author":"Van Der Horst","year":"2024","journal-title":"Immunol Rev"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16828","article-title":"Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation","volume":"22","author":"Huang","year":"2022","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1111\/trf.18447","article-title":"Clinical implications of imlifidase interference in antibody screening and transfusion management","author":"Osmani","year":"2025","journal-title":"Transfusion (Paris)"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004031","article-title":"Imlifidase-generated single-cleaved IgG: implications for transplantation","volume":"106","author":"Bockermann","year":"2022","journal-title":"Transplantation"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment-na\u00efve individuals with relapsing\u2013remitting multiple sclerosis","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS Drugs"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210380","article-title":"Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia","volume":"26","author":"Alinari","year":"2007","journal-title":"Oncogene"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.12.066","article-title":"New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies","volume":"37","author":"Book","year":"2005","journal-title":"Transplant Proc"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3390\/biom11121850","article-title":"CD44: a multifunctional mediator of cancer progression","volume":"11","author":"Hassn Mesrati","year":"2021","journal-title":"Biomolecules"},{"key":"B141","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40164-020-00192-0","article-title":"CD44 as a tumor biomarker and therapeutic target","volume":"9","author":"Xu","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105535","article-title":"Development of a novel anti-CD44 monoclonal antibody for multiple applications against esophageal squamous cell carcinomas","volume":"23","author":"Goto","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B143","doi-asserted-by":"publisher","first-page":"14010\u2013","DOI":"10.1200\/jco.2008.26.15_suppl.14010","article-title":"Human chimeric anti-CD44 antibody ARH460\u201316\u20132 binds leukemic cells and Malignant plasma cells","volume":"26","author":"Guillaume","year":"2008","journal-title":"J Clin Oncol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2007.10.009","article-title":"Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma","volume":"44","author":"Riechelmann","year":"2008","journal-title":"Oral Oncol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3892\/ol.2016.5413","article-title":"Effects of anti-CD44 monoclonal antibody IM7 carried with chitosan polylactic acid-coated nano-particles on the treatment of ovarian cancer","volume":"13","author":"Yang","year":"2017","journal-title":"Oncol Lett"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8687","article-title":"Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia","volume":"7","author":"Vey","year":"2016","journal-title":"Oncotarget"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2087204","article-title":"The importance of CD44 as a stem cell biomarker and therapeutic target in cancer","volume":"2016","author":"Thapa","year":"2016","journal-title":"Stem Cells Int"},{"key":"B148","article-title":"Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients","volume":"6","author":"Stroomer","year":"2000","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11098","article-title":"First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors","volume":"7","author":"Menke-van Der Houven Van Oordt","year":"2016","journal-title":"Oncotarget"},{"key":"B150","first-page":"37","article-title":"The Ina and Inb blood group antigens are located on a glycoprotein of 80,000 MW (the CDw44 glycoprotein) whose expression is influenced by the In(Lu) gene","volume":"64","author":"Spring","year":"1988","journal-title":"Immunology"},{"key":"B151","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/vox.12717","article-title":"International society of blood transfusion working party on red cell immunogenetics and blood group terminology: report of the dubai, copenhagen and toronto meetings","volume":"114","author":"Storry","year":"2019","journal-title":"Vox Sang"},{"key":"B152","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13054-016-1208-6","article-title":"An antibody against a novel high incidence antigen in the Indian blood group system","volume":"113","author":"Henny","year":"2018","journal-title":"Vox Sang"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3390\/cells12121605","article-title":"The role of CD36 in cancer progression and its value as a therapeutic target","volume":"12","author":"Feng","year":"2023","journal-title":"Cells"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-1409","article-title":"PLT012, a humanized CD36-blocking antibody, is effective for unleashing antitumor immunity against liver cancer and liver metastasis","volume":"15","author":"Tzeng","year":"2025","journal-title":"Cancer Discov"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2001.41030375.x","article-title":"Neonatal alloimmune thrombocytopeniadue to anti\u2010Naka","volume":"41","author":"Kankirawatana","year":"2001","journal-title":"Transfusion (Paris)"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1159\/000461044","article-title":"A new platelet-specific antigen, Naka, involved in therefractoriness of HLA-matched platelet transfusion","volume":"57","author":"Ikeda","year":"1989","journal-title":"Vox Sang"},{"key":"B157","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/vox.13595","article-title":"Evidence that CD36 is expressed on red blood cells and constitutes a novel blood group system of clinical importance","volume":"119","author":"Alattar","year":"2024","journal-title":"Vox Sang"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1080\/21623945.2019.1609202","article-title":"Lymphocytes upregulate CD36 in adipose tissue and liver","volume":"8","author":"Couturier","year":"2019","journal-title":"Adipocyte"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.1.230","article-title":"CD36 is differentially expressed on B cell subsets during development and in responses to antigen","volume":"180","author":"Won","year":"2008","journal-title":"J Immunol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1496\u2013","DOI":"10.1182\/blood-2024-207436","article-title":"Results of a phase 1, first-in-human study of INA03, an anti-CD71 antibody-drug conjugate in patients with relapsed or refractory (R\/R) acute leukemias","volume":"144","author":"Garciaz","year":"2024","journal-title":"Blood"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0193","article-title":"Nonclinical efficacy and safety of CX-2029, an anti-CD71 probody\u2013drug conjugate","volume":"21","author":"Singh","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3892\/or.2019.7337","article-title":"A novel therapeutic anti-CD55 monoclonal antibody inhibits the proliferation and metastasis of colorectal cancer cells","volume":"42","author":"Dho","year":"2019","journal-title":"Oncol Rep"},{"key":"B163","doi-asserted-by":"publisher","first-page":"8960","DOI":"10.1038\/s41598-018-27355-8","article-title":"Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer","volume":"8","author":"Dho","year":"2018","journal-title":"Sci Rep"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.21307\/immunohematology-2021-017","article-title":"The Cromer blood group system: an update","volume":"37","author":"Storry","year":"2021","journal-title":"Immunohematology"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.52.6.652","article-title":"Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation","volume":"52","author":"Terstappen","year":"1992","journal-title":"J Leukoc Biol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12553","article-title":"Recombinant blood group proteins facilitate the detection of alloantibodies to high\u2010prevalence antigens and reveal underlying antibodies: results of an international study","volume":"54","author":"Seltsam","year":"2014","journal-title":"Transfusion (Paris)"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.013","article-title":"The B7:CD28 family and friends: Unraveling coinhibitory interactions","volume":"57","author":"Burke","year":"2024","journal-title":"Immunity"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.942665","article-title":"Belatacept in kidney transplantation: What are the true benefits? A systematic review","volume":"9","author":"Lombardi","year":"2022","journal-title":"Front Med"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000325915.00112.61","article-title":"CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial","volume":"71","author":"Viglietta","year":"2008","journal-title":"Neurology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1888597\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T13:41:38Z","timestamp":1786455698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1888597\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":170,"alternative-id":["10.3389\/fimmu.2026.1888597"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1888597","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"1888597"}}